The Zhitong Finance App learned that Weilizhibo-B (09887) rose by more than 7%. As of press release, it had risen 7.02% to HK$44.2, with a turnover of HK$205.967 million.

According to the news, on October 19, Verishibo announced that the full summaries of the six studies independently developed by Verisin® (opatisumimab, anti-PD-L1/4-1BB bispecific antibody) and LBL-034 (GPRC5D/CD3 bispecific T-cell connector, TCE) were published on the official website of the 2026 ESMO Annual Meeting. This data collection shows trends in long-lasting relief and prolonged survival benefits of Velisign® in multiple immune “cold tumors”, supports its potential as a pan-tumor therapy, and highlights the differentiation capabilities of the company's X-body and TCE technology platforms.

Notably, three studies, Verisign® and LBL-034, were selected for ESMO's preferred oral presentation in 2026, and one study was selected as the Breakthrough Summary (LBA). Detailed and updated data on these studies will be released during ESMO's oral report in 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.